Medable, founded in 2015 by a physician-scientist who encountered firsthand the barriers of patient access in clinical research, operates at the intersection of artificial intelligence and life sciences. The company has built the leading technology platform for agentic AI-powered clinical development, fundamentally reshaping how clinical trials are designed and executed on a global scale. Its cloud-based platform enables pharmaceutical sponsors, contract research organizations, healthcare providers, and patients to collaborate seamlessly throughout the trial process.
The company's technical capabilities span agentic AI, electronic Clinical Outcome Assessment (eCOA), decentralized clinical trial solutions, and comprehensive study management tools. Its Studio and AI technology enables sponsors to build studies up to 35 times faster - a measurable advantage in an industry where speed directly impacts patient outcomes. Medable maintains rigorous compliance standards, holding certifications for HIPAA, GDPR, ISO, FDA 21 CFR Part 11, and ICH E6(R2) GCP.
Medable serves clients across pharmaceutical, biotech, and CRO sectors, with applications in therapeutic areas including oncology and vaccines. The company's stated ambition - achieving one-day study startup, one-day patient enrollment, and one-year study conduct timelines - signals a commitment to compressing clinical development timelines that have historically stretched over many years. This mission to accelerate the delivery of effective therapies to patients underpins the company's strategic direction.
